##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 
 FORM 10-Q/A
 (Amendment No.1)
 
 (Mark One)
 þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended June 30, 2008
 OR
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from  to
 001-33357
(Commission file number)
 
 PROTALIX BIOTHERAPEUTICS, INC.
 (Exact name of registrant as specified in its charter)
 
 Florida
    
    65-0643773(State or other jurisdiction 
of incorporation or organization)
    
    (I.R.S. Employer
Identification No.)2 Snunit Street 
Science Park 
POB 455Carmiel, Israel
    
    20100(Address of principal executive offices)
    
    (Zip Code)
 972-4-988-9488  (Registrants telephone number, including area code)
 Securities registered pursuant to Section 12(b) of the Act:
 Title of each class
    
    Name of each exchange on which registeredCommon stock, par value $0.001 per share
    
    American Stock Exchange
 þ o
  Large accelerated filer o
    
    Accelerated filer þ
    
    Non-accelerated filer   o
(Do not check if a smaller reporting company)
    
    Smaller Reporting Company o
 o þ




---



##### 



FORM 10-Q/A
TABLE OF CONTENTS
 PagePART I  FINANCIAL INFORMATIONCautionary Statement Regarding Forward-Looking Statements
    
    iiItem 1. Financial StatementsCondensed Consolidated Balance Sheets 
As of June 30, 2008 (Unaudited) and December 31, 2007
    
    
    1Condensed Consolidated Statements of Operations (Unaudited) 
For the Six Months and the Three Months Ended 
June 30, 2008 and 2007; and for the
Period from December 27, 1993 through June 30, 2008
    
    
    2Condensed Consolidated Statement of Changes in Shareholders Equity 
As of June 30, 2008 (Unaudited) and December 31, 2007
    
    
    3Condensed Consolidated Statements of Cash Flows (Unaudited) 
For the Six Months Ended June 30, 2008 and 2007; and for the Period from December
27, 1993 through June 30, 2008
    
    
    4Notes to Condensed Consolidated Financial Statements
    
    
    6Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    13Item 3. Quantitative and Qualitative Disclosures About Market Risk
    
    
    19Item 4. Controls and Procedures
    
    
    20PART II  OTHER INFORMATIONItem 1. Legal Proceedings
    
    
    22Item 1A. Risk Factors
    
    
    22Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    23Item 3. Defaults Upon Senior Securities
    
    
    23Item 4. Submission of Matters to a Vote of Security Holders
    
    
    23Item 5. Other Information
    
    
    23Item 6. Exhibits
    
    
    24Signatures
    
    
    26EX-31.1: CERTIFICATIONEX-31.2: CERTIFICATIONEX-32.1: CERTIFICATIONEX-32.2: CERTIFICATION
  i




---



##### Table of Contents



Except where the context otherwise requires, the terms, we, us, our or the Company, refer
to the business of Protalix BioTherapeutics, Inc. and its consolidated subsidiaries, and Protalix
or Protalix Ltd. refers to the business of Protalix Ltd., our wholly-owned subsidiary and sole
operating unit.
 
 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
   
    
    the inherent risks and uncertainties in developing drug platforms and products of
the type we are developing;
    
    delays in our preparation and filing of applications for regulatory approval;
    
    delays in the approval or potential rejection of any applications we file with the
United States Food and Drug Administration, or the FDA, or other regulatory
authorities;
    
    any lack of progress of our research and development (including the results of
clinical trials we are conducting);
    
    obtaining on a timely basis sufficient patient enrollment in our clinical trials;
    
    the impact of development of competing therapies and/or technologies by other
companies;
    
    our ability to obtain additional financing required to fund our research programs;
    
    the risk that we will not be able to develop a successful sales and marketing
organization in a timely manner, if at all;
    
    our ability to establish and maintain strategic license, collaboration and
distribution arrangements and to manage our relationships with collaborators,
distributors and partners;
    
    potential product liability risks and risks of securing adequate levels of product
liability and clinical trial insurance coverage;
    
    the availability of reimbursement to patients from health care payors for our drug
products, if approved;
    
    the possibility of infringing a third partys patents or other intellectual property
rights;
    
    the uncertainty of obtaining patents covering our products and processes and in
successfully enforcing them against third parties;
    
    the possible disruption of our operations due to terrorist activities and armed
conflict, including as a result of the disruption of the operations of regulatory
authorities, our subsidiary, our manufacturing facilities and our customers, suppliers,
distributors, collaborative partners, licensees and clinical trial sites; and
    
    other risks and uncertainties detailed in Section 1A of this Quarterly Report.
  ii




---



##### Table of Contents



EXPLANATORY NOTE
 Share-Based Payment
        iii




---



##### Table of Contents



PART I  FINANCIAL INFORMATION
 
 Item 1. Financial Statements
 PROTALIX BIOTHERAPEUTICS, INC.
 
 CONDENSED CONSOLIDATED BALANCE SHEETS
  June 30, 2008
    
    
    December 31, 2007(Unaudited)ASSETSCURRENT ASSETS:Cash and cash equivalents
    
    $
    53,360
    
    
    $
    61,813Accounts receivable
    
    
    1,920
    
    
    
    1,354Total current assets
    
    
    55,280
    
    
    
    63,167FUNDS IN RESPECT OF EMPLOYEE
RIGHTS UPON RETIREMENT
    
    
    626
    
    
    
    464PROPERTY AND EQUIPMENT, NET
    
    
    5,914
    
    
    
    4,506Total assets
    
    $
    61,820
    
    
    $
    68,137LIABILITIES AND SHAREHOLDERS EQUITYCURRENT LIABILITIES:Accounts payable and accruals:Trade
    
    $
    1,714
    
    
    $
    899Other
    
    
    2,626
    
    
    
    2,863Total current liabilities
    
    
    4,340
    
    
    
    3,762LIABILITY FOR EMPLOYEE RIGHTS
UPON RETIREMENT
    
    
    967
    
    
    
    690Total liabilities
    
    
    5,307
    
    
    
    4,452SHAREHOLDERS EQUITY
    
    
    56,513
    
    
    
    63,685Total liabilities and shareholders equity
    
    $
    61,820
    
    
    $
    68,137
 The accompanying notes are an integral part of the condensed consolidated financial statements.
 1




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
   Period fromDecember 27, 1993*Six Months Ended
    
    
    Three Months Ended
    
    
    throughJune 30, 2008
    
    
    June 30, 2007
    
    
    June 30, 2008
    
    
    June 30, 2007
    
    
    June 30, 2008(restated)
    
    
    
    
    
    (restated)
    
    
    (restated)REVENUES
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    830COST OF REVENUES
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    206GROSS PROFIT
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    624RESEARCH AND DEVELOPMENT 
EXPENSES (1)
    
    $
    9,684
    
    
    $
    6,401
    
    
    $
    4,031
    
    
    $
    3,175
    
    
    
    41,986less  grants
    
    
    (2,515
    )
    
    
    (1,081
    )
    
    
    (1,149
    )
    
    
    (343
    )
    
    
    (8,702
    )7,169
    
    
    
    5,320
    
    
    
    2,882
    
    
    
    2,832
    
    
    
    33,284GENERAL AND ADMINISTRATIVE 
EXPENSES (2)
    
    
    3,992
    
    
    
    12,755
    
    
    
    2,016
    
    
    
    6,363
    
    
    
    33,588OPERATING LOSS
    
    
    11,161
    
    
    
    18,075
    
    
    
    4,898
    
    
    
    9,195
    
    
    
    66,248FINANCIAL INCOME  NET
    
    
    (1,819
    )
    
    
    (506
    )
    
    
    (669
    )
    
    
    (175
    )
    
    
    (4,267
    )OTHER INCOME
    
    
    
    
    
    
    (6
    )
    
    
    
    
    
    
    (6
    )
    
    
    (6
    )NET LOSS BEFORE CHANGE IN
ACCOUNTING PRINCIPLE
    
    
    9,342
    
    
    
    17,563
    
    
    
    4,229
    
    
    
    9,014
    
    
    
    61,975CUMULATIVE EFFECT OF
CHANGE IN ACCOUNTING PRINCIPLE
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (37
    )NET LOSS FOR THE PERIOD
    
    $
    9,342
    
    
    $
    17,563
    
    
    $
    4,229
    
    
    $
    9,014
    
    
    $
    61,938NET LOSS PER SHARE OF COMMON 
STOCK  BASIC AND DILUTED:
    
    $
    0.12
    
    
    $
    0.27
    
    
    $
    0.06
    
    
    $
    0.14WEIGHTED AVERAGE NUMBER OF SHARES OF
COMMON STOCK USED IN COMPUTING LOSS PER
SHARE:Basic and diluted
    
    
    75,855,594
    
    
    
    65,032,809
    
    
    
    75,898,295
    
    
    
    65,657,181(1) Includes share-based compensation
    
    
    672
    
    
    
    1,778
    
    
    
    (655
    )
    
    
    878
    
    
    
    6,056(2) Includes share-based compensation
    
    
    1,495
    
    
    
    11,266
    
    
    
    648
    
    
    
    5,616
    
    
    
    22,495
 
 *
    
    Incorporation date. See Note 1a. The accompanying notes are an integral part of the condensed consolidated financial statements.
 2




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.
 
 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY
  DeficitaccumulatedConvertible
    
    
    
    
    
    
    Convertible
    
    
    
    
    
    
    Additional
    
    
    duringCommon
    
    
    Preferred
    
    
    Common
    
    
    Preferred
    
    
    
    
    
    
    paid-in
    
    
    developmentStock (2)
    
    
    Shares
    
    
    Stock
    
    
    Shares
    
    
    Warrants
    
    
    capital
    
    
    stage
    
    
    TotalNumber of shares
    
    
    AmountBalance at December 27, 1993(1)Changes during the period from
December 27, 1993* through December
31, 2007 (restated):Common Stock and convertible preferred
A, B and C shares and warrants issued
for cash (net of issuance costs of
$5,078)
    
    
    38,856,127
    
    
    
    398,227
    
    
    $
    39
    
    
    $
    1
    
    
    $
    1,382
    
    
    $
    73,836
    
    
    
    
    
    
    $
    75,258Exercise of options granted to
employees and non-employees
    
    
    2,780,467
    
    
    
    847
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    408
    
    
    
    
    
    
    
    411Conversion of convertible preferred
shares into common stock
    
    
    24,375,870
    
    
    
    (399,074
    )
    
    
    24
    
    
    
    (1
    )
    
    
    
    
    
    
    (23
    )Change in accounting principle
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (37
    )
    
    $
    37Expiration of warrants
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (34
    )
    
    
    34Merger with a wholly owned subsidiary
of the Company (net of issuance cost
of $642)
    
    
    583,280
    
    
    
    
    
    
    
    1
    
    
    
    
    
    
    
    
    
    
    
    240
    
    
    
    
    
    
    
    241Exercise of warrants
    
    
    9,171,695
    
    
    
    
    
    
    
    9
    
    
    
    
    
    
    
    (1,348
    )
    
    
    15,342
    
    
    
    
    
    
    
    14,003Restricted common stock issued for
future services
    
    
    8,000
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    11
    
    
    
    
    
    
    
    11Share-based compensation
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    26,394
    
    
    
    
    
    
    
    26,394Net loss for the period
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (52,633
    )
    
    
    (52,633
    )Balance at December 31, 2007 (restated)
    
    
    75,775,439
    
    
    
    
    
    
    
    76
    
    
    
    
    
    
    
    
    
    
    
    116,205
    
    
    
    (52,596
    )
    
    
    63,685Changes during the six month period
ended June 30, 2008(Unaudited):Restricted common stock issued for
future services
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (5
    )
    
    
    
    
    
    
    (5
    )Share-based compensation
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2,172
    
    
    
    
    
    
    
    2,172Exercise (includes Net Exercise) of
options granted to employees
    
    
    154,796
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    3
    
    
    
    
    
    
    
    3Net loss for the period
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (9,342
    )
    
    
    (9,342
    )Balance
at June 30, 2008(Unaudited)
    
    
    75,930,235
    
    
    
    
    
    
    $
    76
    
    
    
    
    
    
    
    
    
    
    $
    118,375
    
    
    $
    (61,938
    )
    
    $
    56,513
 
 *
    
    Represents an amount less than $1.(1)
    
    Incorporation date. See Note 1a.(2)
    
    Common Stock, $0.001 par value; Authorized  as of December 31, 2007 and June 30, 2008 -
150,000,000 shares. The accompanying notes are an integral part of the condensed consolidated financial statements.
 3




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
   Period fromDecember 27, 1993*Six Months Ended
    
    
    throughJune 30, 2008
    
    
    June 30, 2007
    
    
    June 30, 2008(restated)
    
    
    (restated)CASH FLOWS FROM OPERATING ACTIVITIES:Net loss for the period
    
    $
    (9,342
    )
    
    $
    (17,563
    )
    
    $
    (61,938
    )Adjustments required to reconcile net loss to net
cash used in operating activities:
    
    
    
    
    
    
    
    
    
    
    Cumulative effect of change in accounting principle
    
    
    
    
    
    
    
    
    
    
    (37
    )Share based compensation
    
    
    2,167
    
    
    
    13,044
    
    
    
    28,551Financial income net (principal differences relate
to currency transaction 
gains/losses)
    
    
    (916
    )
    
    
    47
    
    
    
    (1,722
    )Depreciation and impairment of fixed assets
    
    
    582
    
    
    
    277
    
    
    
    2,521Changes in accrued liability for employee rights
upon retirement
    
    
    277
    
    
    
    127
    
    
    
    967Gain on amounts funded in respect of employee rights
upon retirement
    
    
    (81
    )
    
    
    (8
    )
    
    
    (185
    )Gain on sale of fixed assets
    
    
    
    
    
    
    (6
    )
    
    
    (6
    )Changes in operating assets and liabilities:Increase in accounts receivable
    
    
    (388
    )
    
    
    (963
    )
    
    
    (1,533
    )Increase in accounts payable and accruals
    
    
    254
    
    
    
    156
    
    
    
    3,261Net cash used in operating activities
    
    $
    (7,447
    )
    
    $
    (4,889
    )
    
    $
    (30,121
    )CASH FLOWS FROM INVESTING ACTIVITIES:Purchase of property and equipment
    
    $
    (1,904
    )
    
    $
    (809
    )
    
    $
    (7,726
    )Investment grant received in respect of fixed assets
    
    
    
    
    
    
    
    
    
    
    38Investment in restricted cash deposit
    
    
    
    
    
    
    
    
    
    
    (47
    )Proceeds from sale of property and equipment
    
    
    
    
    
    
    10
    
    
    
    11Amounts funded in respect of employee rights upon
retirement
    
    
    (81
    )
    
    
    (59
    )
    
    
    (612
    )Amounts paid in respect of employee rights upon
retirement
    
    
    
    
    
    
    14
    
    
    
    171Net cash used in investing activities
    
    $
    (1,985
    )
    
    $
    (844
    )
    
    $
    (8,165
    )CASH FLOWS FROM FINANCING ACTIVITIES:Loan and convertible bridge loan received
    
    
    
    
    
    
    
    
    
    $
    2,145Repayment of loan
    
    
    
    
    
    
    
    
    
    
    (1,000
    )Issuance of shares and warrants, net of issuance cost
    
    
    (56
    )
    
    $
    12,910
    
    
    
    74,059Exercise of options and warrants
    
    $
    3
    
    
    
    
    
    
    
    14,417Merger with a wholly owned subsidiary of the
Company, net of issuance cost
    
    
    
    
    
    
    (39
    )
    
    
    237Net cash (used) provided by financing activities
    
    $
    (53
    )
    
    $
    12,871
    
    
    $
    89,858EFFECT OF EXCHANGE RATE CHANGES
ON CASH
    
    $
    1,032
    
    
    $
    (27
    )
    
    $
    1,788NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    
    
    (8,453
    )
    
    
    7,111
    
    
    
    53,360BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF
PERIOD
    
    
    61,813
    
    
    
    15,378
    
    
    
    BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD
    
    $
    53,360
    
    
    $
    22,489
    
    
    $
    53,360
 The accompanying notes are an integral part of the condensed consolidated financial statements.
 4




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.   CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
  Period fromDecember 27,1993*Six Months Ended
    
    
    throughJune 30, 2008
    
    
    June 30, 2007
    
    
    June 30, 2008(restated)
    
    
    (restated)SUPPLEMENTARY DISCLOSURE OF
CASH FLOW INFORMATION:Cash paid during the period for interest
    
    
    
    
    
    
    
    
    
    $
    80SUPPLEMENTARY INFORMATION
ON INVESTING AND FINANCING
ACTIVITIES NOT INVOLVING CASH FLOWS:Conversion of convertible bridge loan into shares
    
    
    
    
    
    
    
    
    
    $
    1,145Purchase of property and equipment
    
    $
    752
    
    
    $
    451
    
    
    $
    752Issuance cost not yet paid and accruals  other:
    
    $
    5
    
    
    $
    5
    
    
    $
    5Issuance cost paid by a grant of options
    
    
    
    
    
    
    
    
    
    $
    21Consultants and director credit balance converted
into shares
    
    
    
    
    
    
    
    
    
    $
    80Merger with a wholly-owned subsidiary of
the CompanyIssuance cost setoff against accounts payable
    
    
    
    
    
    $
    65
 
 *
    
    Incorporation date. See Note 1a. The accompanying notes are an integral part of the condensed consolidated financial statements.
 5




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.
 
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
   NOTE 1  SIGNIFICANT ACCOUNTING POLICIES
 a.
    
    General
 1.
    
    OperationProtalix BioTherapeutics, Inc. and its wholly-owned subsidiary, Protalix Ltd.
(collectively, the Company), are biopharmaceutical companies focused on the
development and commercialization of recombinant therapeutic proteins based on the
Companys proprietary ProCellExtm protein expression system
(ProCellEx). The Companys lead product development candidate is prGCD for the
treatment of Gaucher disease, which the Company is developing using its ProCellEx
protein expression system. The Company is currently enrolling and treating patients
in a phase III clinical trial of prGCD, and has initiated an extension study in
connection with the trial for patients that have completed the trial and chose to
continue the treatment.The Company has been in the development stage since its inception. The Companys
successful completion of its development program and its transition to normal
operations is dependent upon the Companys receipt of necessary regulatory approvals
from the United States Food and Drug Administration (FDA) prior to selling its
products within the United States, and foreign regulatory approvals must be obtained
to sell its products internationally. There can be no assurance that the Companys
products will receive regulatory approvals, and a substantial amount of time may
pass before the Company achieves a level of sales adequate to support the Companys
operations, if at all. The Company will also incur substantial expenditures in
connection with the regulatory approval process and it might need to raise
additional capital during the developmental period. Obtaining marketing approval
will be directly dependent on the Companys ability to implement the necessary
regulatory steps required to obtain marketing approval in the United States and
other countries and the success of the Companys clinical trials. The Company
cannot predict the outcome of these activities.2.
    
    Liquidity and Financial ResourcesThe Company currently does not have sufficient resources to complete the
commercialization of any of its proposed products. Based on its current cash
resources and commitments, the Company believes it will be able to maintain its
current planned development activities and the corresponding level of expenditures
for at least the next 24 months, although no assurance can be given that it will not
need additional cash prior to such time. If there are unexpected increases in
general and administrative expenses, capital expenditures and research and
development expenses, the Company may need to seek additional financing during the
next 24 months.
 b.
    
    General Basis of Presentation
 The accompanying unaudited condensed consolidated financial statements of the
Company have been prepared in accordance with generally accepted accounting
principles in the United States (GAAP) for interim financial information,
Statement of Financial Accounting Standards (SFAS) No. 7, Accounting and
Reporting by Development Stage Enterprises, and Article 10 of Regulation S-X under
the Securities Exchange Act of 1934. Accordingly, they do not include all of the
information and notes required by GAAP for complete financial statements. In the
opinion of management, all adjustments (of a normal recurring nature) considered
necessary for a fair statement of the results for the interim periods presented have
been included. Operating results for the interim period are not necessarily
indicative of the results that may be expected for the full year. These unaudited
condensed consolidated financial statements should be read in
 6




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.   NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 NOTE 1  SIGNIFICANT ACCOUNTING POLICIES (continued):
 conjunction with the audited consolidated financial statements in the Annual Report
on Form 10-K for the year ended December 31, 2007, filed by the Company with the
Securities and Exchange Commission (the Commission). The comparative balance
sheet at December 31, 2007 has been derived from the audited financial statements at
that date, but does not include all of the information and notes required under GAAP
for complete financial statements.
 c.
    
    Net loss per share
 Basic and diluted loss per share (LPS) are computed by dividing net loss by the
weighted average number of shares of the Companys common stock, par value $.001 per
share (the Common Stock), outstanding for each period.Shares of restricted Common Stock and the shares of Common Stock underlying
outstanding options and warrants of the Company were not included in the calculation
of diluted LPS because the effect would be anti-dilutive.Diluted LPS does not include options, restricted shares of Common Stock and warrants
of the Company in the amount of 12,404,378 and 10,883,292 shares of Common Stock for
the six months ended June 30, 2007 and 2008, respectively, and 11,801,505 and
11,181,138 shares of Common Stock for the three months ended June 30, 2007 and 2008,
respectively.
 d.
    
    Newly issued Accounting Pronouncements
 1.
    
    In December 2007, the Financial Accounting Standards Board (the FASB)
issued SFAS No. 141 (revised 2007), Business Combinations (SFAS 141(R)). SFAS
141(R) changes the accounting for business combinations, including the measurement
of acquirer shares issued in consideration for a business combination, the
recognition of contingent consideration, the accounting for contingencies, the
recognition of capitalized in-process research and development, the accounting for
acquisition-related restructuring cost accruals, the treatment of acquisition
related transaction costs and the recognition of changes in the acquirers income
tax valuation allowance and income tax uncertainties. SFAS 141(R) applies
prospectively to business combinations for which the acquisition date is on or
after the beginning of the first annual reporting period beginning on or after
December 15, 2008. Early application is prohibited. The Company will be required
to adopt SFAS 141(R) on January 1, 2009.2.
    
    In December 2007, the FASB issued SFAS No. 160, Noncontrolling
Interests in Consolidated Financial Statements, an Amendment of ARB No. 51 (SFAS
160). SFAS 160 amends ARB 51 to establish accounting and reporting standards for
the noncontrolling interest in a subsidiary and for the deconsolidation of a
subsidiary. Ownership interests in subsidiaries held by parties other than the
parent company of the subsidiary are required to be presented in the consolidated
statement of financial position within equity, but separate from the parent
companys equity. SFAS 160 requires that changes in a parent companys ownership
interest while the parent company retains its controlling financial interest in its
subsidiary should be accounted for in a manner similar to the accounting treatment
of equity transactions. When a subsidiary is deconsolidated, any retained
noncontrolling equity investment in the former subsidiary should be initially
measured at fair value, with any gain or loss recognized in earnings. SFAS 160
requires consolidated net income to be reported in amounts that include the amounts
attributable to both the parent company and the noncontrolling interest. It also
requires disclosure, on the face of the consolidated income statement, of the
amounts of consolidated net income attributable to both parent companies and the
noncontrolling interests.
 7




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.   NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 NOTE 1  SIGNIFICANT ACCOUNTING POLICIES (continued):
 SFAS 160 is effective for fiscal years (including interim periods within those
fiscal years) beginning on or after December 15, 2008. Earlier adoption is
prohibited. SFAS 160 is required to be applied prospectively as of the beginning of
the fiscal year in which it is initially applied, except for the presentation and
disclosure requirement which shall be applied retrospectively for all periods
presented. The Company is required to adopt SFAS 160 as of January 1, 2009. The
Company is currently assessing the impact that SFAS 160 may have on its results of
operations and financial position.3.
    
    In December 2007, the FASB ratified EITF Issue No. 07-01, Accounting
for Collaborative Arrangements (EITF 07-01). EITF 07-01 defines collaborative
arrangements and establishes reporting requirements for transactions between
participants in a collaborative arrangement and between participants in the
arrangement and third parties. EITF 07-01 also establishes the appropriate income
statement presentation and classification for joint operating activities and
payments between participants, as well as the sufficiency of the disclosures
related to these arrangements. EITF 07-01 is effective for fiscal years beginning
after December 15, 2008 (January 1, 2009, for the Company). Companies are required
to apply EITF 07-01 using a modified version of retrospective transition for those
arrangements in place at the effective date. In addition, companies are required
to report the effects of the application of EITF 07-01 as a change in accounting
principle through retrospective application to all prior periods presented for all
arrangements existing as of the effective date, unless it is impracticable to apply
the effects of the change retrospectively. The Company is currently assessing the
impact that EITF 07-01 may have on its results of operations and financial
position.4.
    
    In March 2008, the FASB issued SFAS No. 161, Disclosures about
Derivative Instruments and Hedging Activities (SFAS 161). SFAS 161 is intended
to improve financial reporting regarding derivative instruments and hedging
activities by requiring enhanced disclosure to enable investors to better
understand the effects of such derivative instruments and hedging activities on a
companys financial position, financial performance and cash flows. SFAS 161 is
effective for financial statements issued for fiscal years and interim periods
beginning after November 15, 2008, with early application encouraged (January 1,
2009, for the Company). SFAS 161 also improves transparency regarding the location
and amounts of derivative instruments in a companys financial statements; how
derivative instruments and related hedged items are accounted for under Statement
of Financial Accounting Standards No. 133 Accounting for Derivative Instruments
and Hedging Activities; and how derivative instruments and related hedged items
affect a companys financial position, financial performance and cash flows. The
Company is currently evaluating the effect SFAS 161 will have on its financial
statement presentations.5.
    
    In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally
Accepted Accounting Principles (SFAS 162). The statement is intended to improve
financial reporting by identifying a consistent hierarchy for selecting accounting
principles to be used in preparing financial statements that are presented in
conformity with U.S. generally accepted accounting principles (GAAP). SFAS 162
will go into effect 60 days following the Commissions approval of the Public
Company Accounting Oversight Board Auditing amendments to AU Section 411 The
Meaning of Present Fairly in Conformity with Generally Accepted Accounting
Principles. The Company does not expect the adoption of SFAS 162 to have a
material impact on its results of operations and financial position.
 
 8




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.   NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 NOTE 1  SIGNIFICANT ACCOUNTING POLICIES (continued):
 e.
    
    ReclassificationsCertain figures in respect of prior years have been reclassified to conform with the
current year presentation.
 NOTE 2  RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS
     9




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.   NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 NOTE 2  RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS (continued):
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2007
(unaudited)
 As Reported
    
    Adjustment
    
    As RestatedGeneral and Administrative Expenses (1)
    
    $
    6,503
    
    
    $
    -140
    
    
    $
    6,363Operating Loss
    
    
    9,335
    
    
    
    -140
    
    
    
    9,195Net Loss for the Period
    
    
    9,154
    
    
    
    -140
    
    
    
    9,014Net Loss Per Share of Common Stock -Basic and Diluted
    
    
    0.14
    
    
    
    
    
    
    
    0.14(1) Includes share-based compensation
    
    
    5,756
    
    
    
    -140
    
    
    
    5,616
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2007
(unaudited)
 As Reported
    
    Adjustment
    
    As RestatedResearch and development Expenses, Net (1)
    
    $
    4,626
    
    
    $
    694
    
    
    $
    5,320General and Administrative Expenses (2)
    
    
    8,490
    
    
    
    4,265
    
    
    
    12,755Operating Loss
    
    
    13,116
    
    
    
    4,959
    
    
    
    18,075Net Loss for the Period
    
    
    12,604
    
    
    
    4,959
    
    
    
    17,563Net Loss Per Share of Common Stock -Basic and Diluted
    
    
    0.19
    
    
    
    0.08
    
    
    
    0.27(1) Includes share-based compensation
    
    
    1,084
    
    
    
    694
    
    
    
    1,778(2) Includes share-based compensation
    
    
    7,001
    
    
    
    4,265
    
    
    
    11,266
 10




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.   NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 NOTE 2  RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS (continued):
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2007
(unaudited)
 As Reported
    
    Adjustment
    
    As RestatedNet loss for the period
    
    $
    (12,604
    )
    
    $
    (4,959
    )
    
    $
    (17,563
    )Adjustments required to
reconcile net loss to net
cash used in operating
activities:Share based compensation
    
    
    8,085
    
    
    
    4,959
    
    
    
    13,044
  NOTE 3  STOCK TRANSACTIONS
 a.
    
    During the three months ended June 30, 2008, the Company issued 154,796 shares
of Common Stock in connection with the exercise of 189,460 options by certain officers
and employees of the Company. The Company received cash proceeds equal to $3 in
connection with such exercises as 167,440 of such options were exercised on a
net-exercise basis.b.
    
    On February 7, 2008, the Companys board of directors approved the grant of
options to purchase 50,000 shares of Common Stock to a newly appointed member of the
Companys board of directors, at an exercise price of $3.02 per share. The options
vest over a four-year period and are exercisable for a 10-year period commencing on the
date of grant.The Company estimated the fair value of the options on the date of the grant using the
Black-Scholes option-pricing model to be approximately $109, based on the following
assumptions: dividend yield of 0% for all years; expected volatility of 62.5%; risk-free
interest rates of 2.9%; and expected life of 10 years.c.
    
    On February 7, 2008, the Companys board of directors approved the grant of
options to purchase 1,900,000 shares of Common Stock, in the aggregate, to certain
officers and employees of the Company, at an exercise price of $5.00 per share. The
options vest variably over periods of up to five years and are exercisable for a
10-year period commencing on the date of grant.The Company estimated the fair value of the options on the date of the grant using the
Black-Scholes option-pricing model to be approximately $2,766, based on the following
assumptions: dividend yield of 0% for all years; expected volatility of 62.5%; risk-free
interest rates of 2.9%; and expected life of six years.d.
    
    In February 2008, the Company amended the stock option agreements of certain
executive officers. As amended, such stock option agreements provide for the full
acceleration of the vesting period of unvested options held by such officers
immediately upon a change of control. The Company concluded that the amendments do not
result in a modification accounting charge against share-based compensation.
 
 11




---



##### Table of Contents



PROTALIX BIOTHERAPEUTICS, INC.   NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 NOTE 4  COMMITMENTS
 a.
    
    In January 2008, the Company entered into a lease agreement for the expansion
of its current facility. The term of the lease is 7.5 years, commencing upon the date
the newly-leased space is ready for occupancy by the Company, with three options for
additional five-year periods, for a total of 15 additional years. The monthly rental
payment is approximately $25 and is subject to increase based on certain improvements
to be performed by the lessor.b.
    
    During the quarter ended June 30, 2008, the Company entered into contracts with
certain third parties in connection with certain clinical services. In accordance with
the terms and conditions of such agreements, commencement of the services will begin in
the quarter ending September 30, 2008. The aggregate fees payable by the Company
during the life of the agreements are equal to approximately $400.
 NOTE 5  FAIR VALUE
      NOTE 6  SUBSEQUENT EVENT
  12




---



##### Table of Contents



Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
 You should read the following discussion and analysis of our financial condition and results of
operations together with our condensed financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form 10-Q and our Annual Report on Form
10-K for the year ended December 31, 2007. Some of the information contained in this discussion
and analysis, particularly with respect to our plans and strategy for our business and related
financing, includes forward-looking statements that involve risks and uncertainties. You should
read Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2007 for a
discussion of important factors that could cause actual results to differ materially from the
results described in or implied by the forward-looking statements contained in the following
discussion and analysis.
 Restatement
 Share-Based Payment
    13




---



##### Table of Contents



Overview
 tm
    14




---



##### Table of Contents



Critical Accounting Policies
  Results of Operations
 Three months ended June 30, 2008 compared to the three months ended June 30, 2007
 Research and Development Expenses
   General and Administrative Expenses
  Financial Expenses and Income
  Six months ended June 30, 2008 compared to the six months ended June 30, 2007
 Research and Development Expenses
  15




---



##### Table of Contents



General and Administrative Expenses
  Financial Expenses and Income
  Liquidity and Capital Resources
 Sources of Liquidity
  Cash Flows
   16




---



##### Table of Contents



Future Funding Requirements
     Effects of Inflation and Currency Fluctuations
   Off-Balance Sheet Arrangements
  17




---



##### Table of Contents



Recently Issued Accounting Pronouncements
      18




---



##### Table of Contents



Item 3. Quantitative and Qualitative Disclosures About Market Risk
 Currency Exchange Risk
   Six months ended
    
    Year endedJune 30,
    
    December 31,2008
    
    2007
    
    2007Average rate for period
    
    
    3.5218
    
    
    
    4.1499
    
    
    
    4.1081Rate at period end
    
    
    3.3520
    
    
    
    4.2490
    
    
    
    3.8460
  Interest Rate Risk
  19




---



##### Table of Contents



Item 4. Controls and Procedures
 Evaluation of Disclosure Controls and Procedures
   Inherent Limitations on Effectiveness of Controls
  20




---



##### Table of Contents



Changes in internal controls
  Management Consideration of Restatement
   21




---



##### Table of Contents



PART II  OTHER INFORMATION
 
 Item 1. Legal Proceedings
  
 Item 1A. Risk Factors
  Trading of our common stock is limited.
     Future sales of our common stock could reduce our stock price.
  22




---



##### Table of Contents



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
 Unregistered Sales of Equity Securities
  Use of Proceeds
    
 Item 3. Defaults Upon Senior Securities
  
 Item 4. Submission of Matters to a Vote of Security Holders
  
 Item 5. Other Information
  23




---



##### Table of Contents



Item 6. Exhibits
 ExhibitNumber
    
    Exhibit Description
    
    Method of Filing3.1
    
    Amended and Restated Articles
of Incorporation of the 
Company
    
    Incorporated by
reference to the
Companys Registration
Statement on Form S-4
filed on March 26,
1998, SEC File No.
333-486773.2
    
    Article of Amendment to
Articles of Incorporation
dated June 9, 2006
    
    Incorporated by
reference to the
Companys Registration
Statement on Form 8-A
filed on March 9,
2007, SEC File No.
001-333573.3
    
    Article of Amendment to
Articles of Incorporation
dated December 13, 2006
    
    Incorporated by
reference to the
Companys Registration
Statement on Form 8-A
filed on March 9,
2007, SEC File No.
001-333573.4
    
    Article of Amendment to
Articles of Incorporation
dated December 26, 2006
    
    Incorporated by
reference to the
Companys Registration
Statement on Form 8-A
filed on March 9,
2007, SEC File No.
001-333573.5
    
    Article of Amendment to
Articles of Incorporation
dated February 26, 2007
    
    Incorporated by
reference to the
Companys Registration
Statement on Form 8-A
filed on March 9,
2007, SEC File No.
001-333573.6
    
    Amended and Restated By-Laws
    
    Incorporated by reference to the
Companys Quarterly Report on Form 10-Q filed on
August 8, 200831.1
    
    Certification of Chief
Executive Officer
    
    Filed herewith
 24




---



##### Table of Contents



ExhibitNumber
    
    Exhibit Description
    
    Method of Filingpursuant to
Rule 13a-14(a) as adopted
pursuant to Section 302 of the
Sarbanes-Oxley Act of 200231.2
    
    Certification of Chief
Financial Officer pursuant to
Rule 13a-14(a) as adopted
pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
    
    Filed herewith32.1
    
    18 U.S.C. Section 1350, as
adopted pursuant to Section
906 of the Sarbanes-Oxley Act
of 2002, Certification of
Chief Executive Officer
    
    Filed herewith32.2
    
    18 U.S.C. Section 1350, as
adopted pursuant to Section
906 of the Sarbanes-Oxley Act
of 2002, Certification of
Chief Financial Officer
    
    Filed herewith
 25




---



##### Table of Contents



SIGNATURES
  PROTALIX BIOTHERAPEUTICS, INC.
               (Registrant)Date: March 6, 2009
    By:
    /s/ David AviezerDavid Aviezer, Ph.D.President and Chief Executive Officer
(Principal Executive Officer)
    
    
Date: March 6, 2009
    By:
    /s/ Yossi MaimonYossi MaimonChief Financial Officer, Treasurer and Secretary
(Principal Financial and Accounting Officer) 26